Barbara Seliger Selected Research

HLA Antigens (Human Leukocyte Antigens)

1/2022	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.
8/2021	Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma.
3/2021	Relevance of 2'-O-Methylation and Pseudouridylation for the Malignant Melanoma.
1/2020	Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients.
1/2020	HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
1/2018	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.
10/2016	HLA-E expression and its clinical relevance in human renal cell carcinoma.
9/2016	Role of microRNAs on HLA-G expression in human tumors.
5/2016	Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma.
6/2015	Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Seliger Research Topics

Disease

184	Neoplasms (Cancer) 03/2024 - 05/2002
42	Renal Cell Carcinoma (Grawitz Tumor) 04/2023 - 05/2002
35	Melanoma (Melanoma, Malignant) 12/2023 - 05/2002
18	Breast Neoplasms (Breast Cancer) 01/2023 - 01/2004
14	Neoplasm Metastasis (Metastasis) 01/2023 - 02/2004
12	Disease Progression 01/2023 - 03/2006
12	Carcinoma (Carcinomatosis) 01/2022 - 09/2005
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 09/2005
6	Infections 03/2024 - 09/2005
6	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 03/2004
6	Carcinogenesis 07/2020 - 01/2004
5	Virus Diseases (Viral Diseases) 03/2024 - 01/2006
5	Lung Neoplasms (Lung Cancer) 07/2022 - 02/2020
5	Squamous Cell Carcinoma of Head and Neck 01/2021 - 04/2005
4	COVID-19 03/2024 - 01/2021
4	Inflammation (Inflammations) 01/2024 - 12/2014
3	Leukemia 04/2023 - 04/2005
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 02/2007
3	Hypoxia (Hypoxemia) 08/2016 - 05/2015
3	Prostatic Neoplasms (Prostate Cancer) 08/2014 - 10/2009
3	Adenocarcinoma 08/2012 - 03/2004
3	Ovarian Neoplasms (Ovarian Cancer) 10/2009 - 11/2003
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 09/2005

Drug/Important Bio-Agent (IBA)

37	Biomarkers (Surrogate Marker)IBA 10/2023 - 10/2003
35	Proteins (Proteins, Gene)FDA Link 01/2023 - 05/2002
29	Histocompatibility Antigens Class IIBA 05/2023 - 05/2003
24	AntigensIBA 12/2023 - 05/2002
21	HLA-G Antigens (HLA G)IBA 03/2024 - 02/2003
21	MicroRNAs (MicroRNA)IBA 08/2023 - 01/2011
18	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 07/2003
17	CytokinesIBA 01/2024 - 03/2004
14	LigandsIBA 01/2022 - 05/2009
14	Peptides (Polypeptides)IBA 01/2020 - 05/2002
12	Immune Checkpoint InhibitorsIBA 10/2023 - 08/2016
12	AntibodiesIBA 06/2020 - 03/2004
10	InterferonsIBA 04/2023 - 05/2002
9	Messenger RNA (mRNA)IBA 01/2023 - 10/2003
9	ProteomeIBA 05/2014 - 12/2002
8	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2017
7	VaccinesIBA 10/2023 - 12/2002
7	Surface Antigens (Surface Antigen)IBA 08/2020 - 06/2006
7	tapasinIBA 01/2020 - 05/2003
7	HLA-A Antigens (HLA-A)IBA 12/2019 - 10/2009
6	Neoplasm Antigens (Tumor Antigens)IBA 01/2021 - 05/2002
6	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 08/2002
6	Small Interfering RNA (siRNA)IBA 09/2019 - 01/2004
5	Amino Acids FDA Link 11/2020 - 10/2003
5	Monoclonal AntibodiesIBA 01/2019 - 08/2012
4	Mitogen-Activated Protein KinasesIBA 12/2023 - 12/2013
4	BiglycanIBA 01/2023 - 01/2018
4	Programmed Cell Death 1 ReceptorIBA 01/2023 - 04/2016
4	Hormones (Hormone)IBA 06/2022 - 12/2019
4	Complement System Proteins (Complement)IBA 01/2022 - 03/2009
4	Transcription Factors (Transcription Factor)IBA 10/2020 - 10/2014
4	EpitopesIBA 01/2019 - 06/2003
4	HLA-A2 Antigen (HLA A2 Antigen)IBA 01/2011 - 06/2006
3	Formaldehyde (Formol)FDA Link 01/2023 - 05/2003
3	ParaffinIBA 01/2023 - 08/2012
3	Carrier Proteins (Binding Protein)IBA 10/2020 - 08/2016
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 07/2020 - 01/2020
3	Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA 01/2020 - 11/2013
3	transporter associated with antigen processing (TAP)IBA 01/2020 - 05/2003
3	EnzymesIBA 01/2019 - 03/2003
3	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 10/2008
3	Lactic Acid (Lactate)FDA LinkGeneric 11/2016 - 05/2011
3	HLA-DR Antigens (HLA-DR)IBA 06/2015 - 05/2011
3	Interleukin-4 (Interleukin 4)IBA 05/2014 - 03/2004
3	UbiquitinIBA 12/2013 - 01/2007
3	HydrolasesIBA 12/2013 - 01/2007
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023 - 08/2015
2	Protein Isoforms (Isoforms)IBA 01/2023 - 10/2004
2	Monophenol Monooxygenase (Tyrosinase)IBA 01/2023 - 05/2002
2	Interleukin-10 (Interleukin 10)IBA 01/2023 - 06/2015
2	LuciferasesIBA 01/2023 - 01/2020
2	Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)IBA 01/2023 - 01/2020
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2023 - 01/2023
2	Bovine Serum AlbuminIBA 01/2023 - 01/2020
2	Small Leucine-Rich ProteoglycansIBA 01/2023 - 01/2019
2	Proteoglycans (Proteoglycan)IBA 01/2023 - 01/2019
2	Indicators and Reagents (Reagents)IBA 01/2022 - 01/2021
2	Histocompatibility Antigens Class IIIBA 08/2021 - 01/2017
2	Member 2 Subfamily B ATP Binding Cassette TransporterIBA 08/2020 - 01/2020
2	Glycoproteins (Glycoprotein)IBA 11/2019 - 04/2005
2	Extracellular Matrix ProteinsIBA 01/2018 - 01/2018
2	Natural Cytotoxicity Triggering Receptor 1IBA 01/2018 - 01/2018
2	Fibronectins (Fibronectin)IBA 01/2018 - 01/2018
2	ElementsIBA 11/2017 - 08/2016
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2017 - 06/2003
2	ChemokinesIBA 04/2016 - 04/2016
2	Glucose (Dextrose)FDA LinkGeneric 05/2015 - 05/2011
2	micaIBA 10/2014 - 03/2012
2	Complementary DNA (cDNA)IBA 05/2014 - 03/2009
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2013 - 04/2005

Therapy/Procedure

55	Immunotherapy 01/2024 - 06/2003
55	Therapeutics 01/2024 - 06/2003
11	Drug Therapy (Chemotherapy) 10/2023 - 01/2007
4	Radiotherapy 08/2023 - 04/2015
3	Transplantation 12/2013 - 05/2009
2	Neoadjuvant Therapy 01/2022 - 12/2019
2	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2021 - 01/2018